ZOLEDRONIC ACID- zoledronic acid injection

País: Estats Units

Idioma: anglès

Font: NLM (National Library of Medicine)

ingredients actius:

ZOLEDRONIC ACID (UNII: 6XC1PAD3KF) (ZOLEDRONIC ACID ANHYDROUS - UNII:70HZ18PH24)

Disponible des:

Cipla USA Inc.

Vía de administración:

INTRAVENOUS

tipo de receta:

PRESCRIPTION DRUG

indicaciones terapéuticas:

Zoledronic acid injection is indicated for the treatment of hypercalcemia of malignancy defined as an albumin-corrected calcium (cCa) of greater than or equal to 12 mg/dL [3.0 mmol/L] using the formula: cCa in mg/dL= Ca in mg/dL + 0.8 (4.0 g/dL - patient albumin [g/dL]). Zoledronic acid injection is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy. Limitations of Use The safety and efficacy of zoledronic acid in the treatment of hypercalcemia associated with hyperparathyroidism or with other nontumor-related conditions have not been established. Hypersensitivity to Zoledronic Acid or Any Components of Zoledronic Acid Injection Hypersensitivity reactions including rare cases of urticaria and angioedema, and very rare cases of anaphylactic reaction/shock have been reported [see Adverse Reactions

Resumen del producto:

4 mg per 100 mL single-dose ready-to-use vial Carton of 1 Vial                                               NDC 69097-399-44 Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].

Estat d'Autorització:

Abbreviated New Drug Application

Fitxa tècnica

ZOLEDRONIC ACID- ZOLEDRONIC ACID INJECTION
CIPLA USA INC.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
ZOLEDRONIC ACID INJECTION SAFELY AND
EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR ZOLEDRONIC ACID
INJECTION.
ZOLEDRONIC ACID INJECTION, FOR INTRAVENOUS USE
INITIAL U.S. APPROVAL:2001
RECENT MAJOR CHANGES
Warnings and Precautions, Embryo-Fetal Toxicity (5.10) 12/2018
INDICATIONS AND USAGE
Zoledronic acid is a bisphosphonate indicated for the treatment of:
Hypercalcemia of malignancy. (1.1)
Patients with multiple myeloma and patients with documented bone
metastases from solid tumors, in conjunction with
standard antineoplastic therapy. Prostate cancer should have
progressed after treatment with at least one hormonal
therapy. (1.2)
Limitations of Use: The safety and efficacy of zoledronic acid has not
been established for use in hyperparathyroidism or
non-tumor-related hypercalcemia.
DOSAGE AND ADMINISTRATION
Hypercalcemia of malignancy (2.1)
4 mg as a single-use intravenous infusion over no less than 15
minutes.
4 mg as retreatment after a minimum of 7 days.
Multiple myeloma and bone metastasis from solid tumors. (2.2)
4 mg as a single-use intravenous infusion over no less than 15 minutes
every 3-4 weeks for patients with creatinine
clearance of greater than 60 mL/min.
Reduce the dose for patients with renal impairment.
Coadminister oral calcium supplements of 500 mg and a multiple vitamin
containing 400 international units of vitamin D
daily.
Administer through a separate vented infusion line and do not allow to
come in contact with any calcium or divalent cation-
containing solutions. (2.3)
DOSAGE FORMS AND STRENGTHS
4 mg per100 mL single-dose ready-to-use vial (3)
CONTRAINDICATIONS
Hypersensitivity to any component of zoledronic acid injection (4)
WARNINGS AND PRECAUTIONS
Patients being treated with zoledronic acid should not be treated with
Reclast
(5.1) Adequately rehydrate patients with
hypercalcemia of malignancy prior to administrat